Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Farhat Nasim

Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Farhat Nasim

Articles By : Farhat Nasim

Sun Pharma Recalls Dandruff, Acne Drugs, Cipla Pulls Lanreotide In US

Farhat Nasim26 Jan 2026 2:12 PM IST

New Delhi: Drugmakers Sun Pharma and Cipla are recalling products in the US due to manufacturing related issues, according to the US Food and Drug...

Dr Reddys Foils Email Spoofing Scam, Rs 2.16 Cr Recovered by Bengaluru Police

USFDA Issues Post-Application Action Letter to Dr Reddy's Biologics Unit

Farhat Nasim10 Jan 2026 10:29 PM IST

Hyderabad: Dr. Reddy's Laboratories Ltd has received a Post-Application Action Letter (PAAL) from the United States Food and Drug Administration...

Aurobindo Arm CuraTeQ Gets Health Canada NOC for Pegfilgrastim Biosimilar Dyrupe

Farhat Nasim9 Jan 2026 11:36 PM IST

Hyderabad: CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has received a Notice of Compliance (NOC) from...

Gland Pharma Gets USFDA Approval for Olopatadine Ophthalmic Solution

Farhat Nasim8 Jan 2026 6:08 PM IST

Olopatadine Hydrochloride Ophthalmic Solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis, a common...

USFDA Grants Tentative Approval, 180-Day Exclusivity to Granules' Generic Amphetamine XR

Farhat Nasim8 Jan 2026 3:11 PM IST

Hyderabad: Granules Pharmaceuticals, Inc., a wholly owned subsidiary of Granules India Limited, has received tentative approval (TA) from the U.S....

Cipla Reappoints P R Ramesh as Independent Director for Second Term Till 2031

Cipla Partner Pharmathen Receives 9 USFDA Observations

Farhat Nasim7 Jan 2026 8:22 PM IST

Cipla had earlier received final USFDA approval in May 2024 to market its generic Lanreotide injection in multiple strengths.

JB Pharma Q3 FY26 Profit Jumps 22% to Rs 198 Crore on Strong Domestic, International Growth

JB Chemicals to Infuse Up to Rs 18 Crore into Dubai Arm Unique Pharma Labs

Farhat Nasim7 Jan 2026 4:54 PM IST

"The additional investment in equity shares of UPL FZE would be utilized towards operational requirements of UPL FZE," the company said.

Biocon Employee Passes Away in Suspected Workplace Suicide

Farhat Nasim6 Jan 2026 4:54 PM IST

Bengaluru: In a tragic incident, a 26-year-old employee of Biocon Biologics Limited died after allegedly falling from the fifth floor of the company's...

Biocon Biologics Secures BB+ Rating Upgrade from S&P on Improved Financial Metrics

Biocon Strengthens Control Over Biologics Unit, Issues Shares to Mylan, Other Investors

Farhat Nasim6 Jan 2026 3:48 PM IST

Bengaluru: Biocon Limited has allotted shares to Mylan Inc., giving the US-based company a 6.10% stake in Biocon's paid-up share capital through a...

Indian Pharmacopoeia 2026 Adds 121 New Monographs Including Blood Component Standards

Farhat Nasim3 Jan 2026 5:58 PM IST

New Delhi: Union Minister for Health and Family Welfare and Chemicals and Fertilizers, J. P. Nadda, released the Indian Pharmacopoeia 2026 (IP 2026)-...

Leadership Change at DoP: Senior IAS Officer Manoj Joshi Takes Charge as Pharma Secretary

Farhat Nasim3 Jan 2026 5:17 PM IST

New Delhi: Senior IAS officer Manoj Joshi has taken charge as the new Secretary of the Department of Pharmaceuticals (DoP) under the Ministry of...

Torrent Pharma Gets Zero USFDA Observations for Dahej Plant

Setback to Corcept Therapeutics: USFDA Declines Approval for Relacorilant in Cushing's-Linked Hypertension

Farhat Nasim3 Jan 2026 4:41 PM IST

The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.

Journal Club Today

Health News Today

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok